SBIR/STTR Award attributes
In the proposed Phase II studywe will further develop our PathMAPImmunotherapy test to address an unmet clinical need within the NSCLC patient populationWe hope to create a test that is able to accurately predict clinical response to PDPD Ltargeted immune checkpoint inhibitors alone and in combination with chemotherapiesOur development work in Phase II will be based on our initial work performed in Phase I and our extensive experience designing and developing PathMAP testsThe PathMAP Immunotherapy test will predict therapeutic response by eliciting and categorizing NSCLC samplesdynamic biomarker responses to biologically relevant modulators and chemotherapy agentsIn this waywe will be able to characterize each tumor s intrinsic resistance mechanismsand how these mechanisms impact key biomarker expression capabilitiesThis ex vivo approach will be made possible by the SnapPathCancer Diagnostics Systemwhich automates and standardizes live solid tumor processing and functional interrogationto enable highly predictive tests in patients with solid tumorsTo our knowledgethe PathMAP Immunotherapy test will represent the first time ex vivo technology has been used in a diagnostic test to predict patient responses to any immunotherapeutic drug
